Capstone Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $578K | Buy |
4,602
+1,451
| +46% | +$182K | ﹤0.01% | 514 |
|
|
2025
Q1 | $349K | Buy |
+3,151
| New | +$349K | ﹤0.01% | 449 |
|
|
2024
Q2 | – | Sell |
-5,652
| Closed | -$780K | – | 1299 |
|
|
2024
Q1 | $780K | Buy |
5,652
+3,258
| +136% | +$449K | ﹤0.01% | 640 |
|
|
2023
Q4 | $315K | Sell |
2,394
-954
| -28% | -$126K | ﹤0.01% | 683 |
|
|
2023
Q3 | $377K | Buy |
+3,348
| New | +$377K | ﹤0.01% | 695 |
|
|
2018
Q1 | – | Sell |
-6,469
| Closed | -$501K | – | 342 |
|
|
2017
Q4 | $501K | Buy |
+6,469
| New | +$501K | 0.01% | 184 |
|
|
2017
Q3 | – | Sell |
-6,800
| Closed | -$312K | – | 561 |
|
|
2017
Q2 | $312K | Sell |
6,800
-8,507
| -56% | -$390K | 0.01% | 408 |
|
|
2017
Q1 | $662K | Buy |
+15,307
| New | +$662K | 0.02% | 389 |
|